Use of transgenic *Aedes aegypti* in Brazil: risk perception and assessment

Paulo Paes de Andrade, Francisco José Lima Aragão, Walter Colli, Odir Antônio Dellagostin, Flávio Finardi-Filho, Mario Hiyoyuki Hirata, Amaro de Castro Lira-Neto, Marcia Almeida de Melo, Alexandre Lima Nepomuceno, Francisco Gorgônio da Nóbrega, Gutemberg Delfino de Sousa, Fernando Hercos Valicente & Maria Helena Bodanese Zanettini

**Abstract** The OX513A strain of *Aedes aegypti*, which was developed by the British company Oxitec, expresses a self-limiting transgene that prevents larvae from developing to adulthood. In April 2014, the Brazilian National Technical Commission on Biosafety completed a risk assessment of OX513A and concluded that the strain did not present new biological risks to humans or the environment and could be released in Brazil. At that point, Brazil became the first country to approve the unconstrained release of a genetically modified mosquito. During the assessment, the commission produced a comprehensive list of – and systematically analysed – the perceived hazards. Such hazards included the potential survival to adulthood of immature stages carrying the transgene – should the transgene fail to be expressed or be turned off by exposure to sufficient environmental tetracycline. Other perceived hazards included the potential allergenicity and/or toxicity of the proteins expressed by the gene, the potential for gene flow or increased transmission of human pathogens and the occupation of vacant breeding sites by other vector species. The Zika epidemic both elevated the perceived importance of *Ae. aegypti* as a vector – among policy-makers and regulators as well as the general public – and increased concerns over the release of males of the OX513A strain. We have therefore reassessed the potential hazards. We found that release of the transgenic mosquitoes would still be both safe and of great potential value in the control of diseases spread by *Ae. aegypti*, such as chikungunya, dengue and Zika.

**Introduction**

In April 2014, Brazil’s National Technical Commission on Biosafety – the agency officially responsible for the assessment of the risks posed by genetically modified organisms in Brazil – assessed the potential risks of the release in Brazil of the transgenic OX513A strain of *Aedes aegypti* and concluded that such a release would be safe.1 At that point, Brazil became the first country to approve the unconstrained release of a genetically modified mosquito. Two years later, however, the Zika epidemic had added to the general public’s concerns over the release of mosquitoes and we therefore decided to re-investigate the perceived risks and update the commission’s risk assessment.

**Control of arbovirus vectors**

Several arboviruses – for example chikungunya virus, dengue viruses and, more recently, Zika virus – cause much human suffering in Brazil.2,3 In 2015, for example, there were more than 1.5 million suspected cases of dengue fever in the country.2 While attempts to create effective or cost–effective vaccines continue, control of the mosquito vectors remains of the utmost importance.7 Brazil has had some success in controlling mosquitoes, even early in the 20th century when no effective insecticides were available.3 Mosquito control, by residents, health workers and other municipal workers supported by a heterogeneous and broad set of collaborators, remains the focus of the National Dengue Control Programme.4 However, the failure of this programme to reduce vector populations to levels that could interrupt dengue transmission5 has spurred Brazilian interest in dengue vaccines6 and novel approaches to vector control such as the sterile insect technique.7–13 The International Atomic Energy Agency describes the sterile insect technique as “a type of birth control in which wild female insects of the pest population do not reproduce when they are inseminated by released, radiation-sterilized males”.13,14 Although sequential releases of large numbers of the sterilized males should lead to a reduction in the size of the pest population, the irradiation used can reduce the released insects’ competitiveness – and this appears to be a particular problem when the insects involved are mosquitoes.15 Over the last decade, as an alternative to the sterile male technique, the genetic modification of mosquitoes, with the production of large numbers of males and females that carry a self-limiting transgene, has been investigated.16 Once released in the environment, the male insects carrying the transgene – which have to be produced in the presence of a selective agent that blocks the transgene’s expression – should, potentially, compete on equal terms with the wild males.17–20

The OX513A strain of *Ae. aegypti*, which was developed by the British company Oxitec, expresses a self-limiting...
dominant transgene that is able to kill, at larval stage, the mosquitoes in which it is expressed (Fig. 1). In the presence of tetracycline, the transgene is either not expressed or is only expressed at a very low and non-lethal level. Once released in the environment, most males carrying the transgene die after about two days.

### Risk perceptions and assessments

In almost all countries, any living modified organism derived from modern biotechnology is very strictly regulated and subjected to a long and detailed risk assessment. In Brazil, which is a Party to the Cartagena Protocol on Biosafety to the Convention on Biological Diversity, such risk assessment is the sole responsibility of National Technical Commission on Biosafety. The commission consists of 27 members and an equal number of surrogates – chosen by various federal government agencies and civil organizations – including highly qualified scientists from across the country. As stipulated in the Cartagena Protocol, any risk assessment of a genetically modified product has to be supported with so-called hard data and preferably with hard data collected in the country that intends to use the product. In 2011, the commission was asked to conduct a risk assessment of the biosafety of the OX513A strain of *Ae. aegypti* as a precursor to the experimental, small-scale release of adult males of the strain in Brazil’s Bahia state – first in Juazeiro and then in Jacobina – that would take place from 2012 to 2014. The commission used data collected in these releases and in field experiments conducted in the Cayman Islands and Malaysia, along with some relevant laboratory results, to produce a comprehensive risk assessment. In April 2014, on the basis of this assessment, the commission approved the OX513A strain for unconstrained release throughout Brazil, primarily as a method of dengue control.

Risk assessments by the commission, like those by most agencies tasked with assessing the risks posed by the release of a genetically modified organism, consist of four main steps, which comply with the Cartagena Protocol: (i) problem formulation; (ii) risk characterization; (iii) risk classification; and (iv) an overall safety evaluation. In problem formulation, specialists outline the release scenario and list all the associated hazards – as perceived by themselves, by other specialists and by the general public. Each perceived hazard is then assessed in the context of the planned release, using any relevant data that are available and considering each plausible route by which the hazard may cause harm. In this risk characterization, any perceived hazards that cannot plausibly lead to harm are excluded. In the subsequent risk classification, the risk of each of the remaining perceived hazards occurring is estimated. Finally, the assessors estimate the overall risk posed by the planned release and consider whether the organism should be considered safe for the environment.

Although international guidelines on the assessment of food safety do not apply directly to mosquitoes, they can still be useful in assessing the allergenicity and toxicity of novel proteins created as the result of the genetic modification of such insects.

### 2014 assessment

As part of its risk assessments of the OX513A strain in 2014, the Technical Commission listed the potential hazards. Although some of the listed hazards were perceived by specialists, most had been voiced by the general public. Among the main perceived hazards were the unexpected survival of at least some of the mosquitoes that carried the transgene and/or their progeny as the result of partial penetration and/or the presence of tetracycline in the environment, allergenicity and/or toxicity of two new proteins expressed, possibly in the mosquitoes’ saliva, as a result of the genetic modification, the vertical and horizontal flow of the transgene and its consequences, the participation of transgenic mosquitoes in the transmission of dengue viruses and the occupation, by other vector species, of breeding sites made vacant by the intervention. Only one of the listed perceived hazards – that is, survival in the presence of tetracycline – was considered plausible, and even that hazard was deemed unlikely since concentrations of tetracycline found in freshwater are usually more than two orders of magnitude lower than that needed to block the transgene’s expression in laboratory-bred insects. In addition, only 50% of the progeny of any female mosquitoes carrying the transgene into adulthood would carry the lethal gene – and they all die at the larval stage if not also protected by exceptionally high concentrations of tetracycline. Although the occupation of breeding sites cleared of *Ae. aegypti* by other vector species – for example *Ae. albopictus* – was deemed a negligible risk by the entomologists involved in the risk assessment, it remained an area of concern among a few of the commission’s non-specialists.

The commission approved the nationwide release of adult males of the OX513A strain on the condition that Oxitec investigated tetracycline concentrations in potential breeding sites by means of periodic literature reviews and also investigated the occupation of cleared breeding sites by *Ae. albopictus*. 
2016 reassessment

By 2016, the recent Zika outbreak had led to additional concerns about the release of any *Ae. aegypti* in Brazil, although few of these concerns had been voiced by universities, research centres or official risk assessment agencies. Such new concerns had arisen even though, by 2016, the usefulness of genetic modification in the control of mosquitoes had been demonstrated in Brazil and elsewhere, and there appeared to be ever-growing acceptance of such an approach to vector control among the general public and public health managers. Among the new concerns were the potential participation of released mosquitoes or their progeny in the transmission of Zika virus, and the perceived possibility of horizontal gene transfer from the transgenic mosquitoes to the Zika virus – potentially making the virus more harmful to humans. Although to us neither of these newly perceived adverse effects of the release of transgenic mosquitoes in Brazil appeared plausible, in April 2016 we reassessed the general safety of the unconstrained release of males of the OX513A strain of *Ae. aegypti* in Brazil.

The plans for the commercial releases of males of the OX513A strain throughout Brazil have not been changed since the 2014 risk assessment. It is expected that the releases will take place mainly in cities or other densely populated areas, in association with other control measures and under continuous surveillance by the relevant municipal health authorities and Oxitec. At the time of writing, a large-scale but still pre-commercial release is in progress in Piracicaba county in São Paulo state. The data already collected during this release (Fig. 2) confirm the effectiveness of such releases, support the encouraging results previously obtained in the Cayman Islands, Malaysia and the Brazilian town of Juazeiro, and the commission’s earlier conclusion that such releases are safe.

As male mosquitoes do not feed on blood, the intention is to release only male *Ae. aegypti*. However, there is a small margin of error during the separation of males and females before field release and therefore up to 0.2% of the released insects may be females. Although the bites of the released females are clearly perceived as a risk by the general public, they are relatively rare and most of the released females will be dead within two days, too soon for them to become infectious even if they have taken a blood meal that contains chikungunya virus, dengue virus or Zika virus. Even if, as may occasionally happen, a female carrying the transgene survives long enough to become infectious, there is no evidence that it will be any worse as a vector than a wild *Ae. aegypti*.

As genomic analyses have revealed many examples of gene transfer between distinct taxa, horizontal gene transfer is always a controversial issue in discussions about the unanticipated risks of releasing a genetically modified organism. However, such gene transfers appear to be very infrequent. There is evidence of horizontal gene transfers from invertebrates to mammals but all such transfers that have been detected appear to be transposon-dependent and very infrequent. It does not seem possible that the piggyBac transposon used in the construction of the OX513A strain of *Ae. aegypti* could mediate the transfer of genetic information from the mosquito to other genomes. This transposon does not codify transposase and, since transposase is not codified in the mosquito’s genome, the insert cannot be remobilized.

Even if a transposase were present, there seems to be no risk of genetic transfer between the OX513A strain’s transgene and the Zika virus because the viral genome is made of single-stranded ribonucleic acid, which is not a substrate for transposases. When, in an effort to understand the Zika outbreak in Brazil, various isolates of the Zika virus were sequenced, no evidence was found for transposon insertion or any other form of horizontal gene transfer.

Conclusion

After circulating around the world, the Zika virus is rapidly spreading through the Americas. The detection of an association between microcephaly in a baby and maternal infection with Zika virus has greatly increased the perceived importance of the primary vector of Zika virus – that is, *Ae. aegypti* – among both the general public and policy-makers. The results of our reassessment of the safety of releasing males of the genetically modified OX513A strain of *Ae. aegypti*, as well as the results of a related assessment by the United States Food and Drug Administration, indicate that releases of such mosquitoes still offer a safe and potentially effective way of reducing wild populations of the vector. The risk-assessment components adopted by both the commission and the United States Food and Drug Administration are those recommended by the World Health Organization. In the ongoing battle against the Zika outbreak, the Brazilian health managers’ choice of control methods has to be based on careful risk assessments and not on risk perceptions. Public perceptions – especially with the advent of fast and global communications via the Internet – are often inaccurate and the general public is often misled by conspiracy theories and
Aedes aegypti, qui a été créée par la société Oxitec, exprime un transgène autolimitant qui empêche la production de moustiques. Nous avons donc réévalué les risques potentiels. Nous estimons que le lâcher de moustiques transgéniques serait à la fois sans danger et extrêmement utile pour lutter contre les maladies transmises par Aedes aegypti en tant que vecteur, et a accru l'inquiétude relative au lâcher de mâles de moustiques transgéniques. En général, nous avons évalué qu'environ un tiers de la population du Brésil était exposé à la transgène – si le transgène ne s'exprime pas ou est désactivé par une exposition à la tétracycline suffisante dans l'environnement. Les autres risques potentiels incluaient les potentialités allergisantes et/ou la toxicité des protéines exprimées par le gène. Rétrospectivement, l'épidémie de virus Zika en 2016 a accentué l'inquiétude relative à l'utilisation de moustiques transgéniques (notamment pour la lutte contre les virus Zika et Zica). Nous avons donc réévalué les risques potentiels. Nous estimons que le lâcher de moustiques transgéniques serait à la fois sans danger et extrêmement utile pour lutter contre les maladies transmises par Aedes aegypti, telles que le chikungunya, la dengue et le virus Zika.
Policy & practice
Safety of transgenic Ae. aegypti in Brazil
Paulo Paes de Andrade et al.

References
1. Technical opinion no. 3964/2014. Brasilia: National Technical Biosafety Commission, 2014. Available from: http://bch.cbd.int/database/attachment/?id=14514 [cited 2016 Feb 16].
2. Monitoramiento dos casos de dengue, fiebre de chikungunya e febre pelo vírus Zika at a Semana Epidemiológica 52, 2015. Bol Epidemiol. 2016;47(3):1–10. [Portuguese.]
3. Zika situation report. Neurological syndrome and congenital anomalies. Geneva: World Health Organization, 2016. Available from: http://apps.who.int/iris/bitstream/10665/204348/1/zikasitrep_5Feb2016_eng.pdf?ua=1. [cited 2016 Feb 19].
4. Kiency MP. WHO research and development on Zika. Geneva: World Health Organization, 2016. Available from: http://www.who.int/mediacentre/commentaries/zika-research-development/en/ [cited 2016 Feb 16].
5. Braga IA, Valle D. Aedes aegypti: histórico do controle no Brasil. Epidemiol Serv Sao Paulo. 2007(16):113–118. [Portuguese.]
6. Programa Nacional de Controle da Dengue. Brasilia: Fundação Nacional de Saúde, 2012. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/pnccd_2002.pdf [cited 2016 Feb 16].
7. Araújo HR, Carvalho DD, Ioshino RS, Costa-da-Silva AL, Capurro ML. Aedes aegypti control strategies in Brazil: incorporation of new technologies to overcome the persistence of dengue epidemics. Insects. 2015 Jun 11;6(2):576–94. doi: http://dx.doi.org/10.3390/insects6020576 PMID: 26463204.
8. Carrasco LR, Lee LK, Lee VJ, Ooi EE, Shepard DS, Then TL, et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Negl Trop Dis. 2011 Dec;5(12):e1426. doi: http://dx.doi.org/10.1371/journal.pntd.0001426 PMID: 22206028.
9. Lindquist DA, Abusowa M, Hall MJ. The New World screwworm fly in Libya: a review of its introduction and eradication. Med Vet Entomol. 1992 Jan;6(1):2–8. doi: http://dx.doi.org/10.1111/j.1439-0418.1995.tb01303.x.
10. Hendrichs J, Franz G, Rendon P. Increased effectiveness and applicability of the sterile insect technique through male-only release for control of Mediterranean fruit-flies during fruiting seasons. J Appl Entomol. 1995 Aug;119(5-6):371–7. doi: http://dx.doi.org/10.1111/j.1439-0418.1995.tb01303.x.
11. Vreysen MJB, Robinson AS. Ionizing radiation and area-wide management of insect pests to promote sustainable agriculture: a review. Agron Sustain Dev. 2011 Jan;31(1):233–50. doi: http://dx.doi.org/10.1051/agro/2010009.
12. Einkerlin W, Gutiérrez-Ruelas JM, Cortes AV, Roldan EC, Midgarden D, Lira E, et al. Area freedom in Mexico from Mediterranean fruit-flies during fruiting seasons. J Appl Entomol. 1995 Jun;118(2):665–81. doi: http://dx.doi.org/10.1051/agro-19950242.
13. Wilke AB, Marrilli MT. Genetic control of mosquitoes: population suppression strategies. Rev Inst Med Trop Sao Paulo. 2012 Sep–Oct;54(5):287–92. doi: http://dx.doi.org/10.1590/S0036-46652012000500009 PMID: 22983293.
14. Sterile insect technique [Internet]. Vienna: International Atomic Energy Agency; 2016. Available from: http://www-naweb.iaea.org/nafa/ipc/stereile-insect-technique.html [cited 2016 Jul 19].

15. Dame DA, Curtis CF, Benedict MQ, Robinson AS, Knols BG. Historical applications of induced sterilisation in field populations of mosquitoes. Malar J. 2009 Nov 16;8 Suppl 2:252. doi: 10.1186/1475-2875-8-S2-52 PMID: 19917072

16. Alphay L. Re-engineering the sterile insect technique. Insect Biochem Mol Biol. 2010 Dec;40(10):1243–7. doi: 10.1016/j.ibmb.2010.05.006 PMID: 21225915

17. Harris AF, Nimmo D, McKemey AR, Kelly N, Scaife S, Donnelly CA, et al. Field performance of engineered male mosquitoes. Nat Biotechnol. 2011 Oct 30;29(11):1034–7. doi: 10.1038/nbt.2019 PMID: 22037378

18. Masonnet-Brunelle B, Corne-Catelin N, Lacroix R, Lees RS, Hoang KP, Nimmo D, et al. Fitness of transgenic mosquito Aedes aegypti males carrying a dominant lethal genetic system. PLoS One. 2013 Oct 3;8(5):e62771. doi: 10.1371/journal.pone.0062711 PMID: 23690948

19. Carvalho DO, McKemey AR, Garziera L, Lacroix R, Donnelly CA, Alphay L, et al. Suppression of a field population of Aedes aegypti in Brazil by sustained release of transgenic male mosquitoes. PLoS Negl Trop Dis. 2015 Oct 2;9(10):e0003964. doi: 10.1371/journal.pntd.0003964 PMID: 26151606

20. Gorman K, Young J, Pineda L, Márquez R, Sosa N, Bernal D, et al. Short-term suppression of Aedes aegypti using genetic control does not facilitate Aedes albopictus. PLoS Manag Sci. 2016 Mar;7(3):e0001618. doi: 10.1371/journal.pone.0001618 PMID: 26374668

21. Phuc HK, Arifin MN, Burton RS, Vasi C, Epton MJ, Pape G, et al. Late-acting dominant lethal genetic systems and mosquito control. BMC Biol. 2007 Mar 20;5(11):11. doi: 10.1186/1471-2142-5-11 PMID: 17374418

22. Smyth SJ, Phillips PW. Risk, regulation and biotechnology: the case of GM crops. GM Crops Food. 2014 Jul 3;5(3):170–7. doi: 10.4161/gmcf.21532

23. Sousa GD, Melo MA, Kido EA, Andrade PF. The Brazilian GMO regulatory scenario and the adoption of agricultural biotechnology. The World of Food Science. 2013. Available from: http://worldfoodscience.com/article/brazilian-gmo-regulatory-scenario-and-adoption-agricultural-biotechnology [cited 2016 Feb 19].

24. Conko G, Kershon DL, Miller H, Parrott WA. A risk-based approach to the regulation of genetically engineered organisms. Nat Biotechnol. 2016 May 6;34(5):493–503. doi: 10.1038/nbt.3568 PMID: 27153279

25. Guidance on risk assessment of living modified organisms. [item 14]. In: Sixth meeting of the Conference of the Parties to the Convention on Biodiversity, Hyderabad, India, 1–5 October. Nairobi: United Nations Environment Programme, 2012. Available from: http://www.cbd.int/doc/meetings/biocmp/official/cop-13-add1-en.pdf [cited 2016 Feb 16].

26. EFSA Panel on Genetically Modified Organisms (GMO). Guidance for risk assessment of food and feed from genetically modified plants. EFSA J. 2011;9(5):2150. doi: 10.2903/j.efsa.2011.2150

27. Lacroix R, McKemey AR, Raduan N, Kwee Wee L, Hong Ming W, Guat Ney L, Sao-paulo/ Available from: [cited 2016 Jul 17].

28. Escobar H. Mosquitos transgénicos podrían combatir dengue e Zika en Sao Paulo [Internet]. Sao Paulo: El Estado de Sao Paulo; 2016 Jan 20. Available from: http://www.fda.gov/downloads/AnimalVeterinary/DevelopmentApprovalProcess/InvestigationalNewDrug/fox-3-0061671.pdf [cited 2016 Feb 19].

29. Joy TK, Jeffrey Gutierrez EH, Ernst K, Walker KR, Carriere Y, Torabi M, et al. Aging field collected Aedes aegypti to determine their capacity for dengue transmission in the southwestern United States. PLoS One. 2012;7(10):e46946. doi: 10.1371/journal.pone.0046946 PMID: 23077356

30. Lee HI, Jako H, Namzi WA, Vasan SS. Comparative life parameters of transgenic and wild strain of Aedes aegypti in the laboratory. Dengue Bull. 2009 Dec;33:103–14.

31. Crisp A, Boschetti C, Perry M, Tunnacclife A, Micklem G. Expression of multiple horizontally acquired genes is a hallmark of both vertebrate and invertebrate genomes. Genome Biol. 2015 Mar 13;16(1):50. doi: http://dx.doi.org/10.1186/s13059-015-0607-3 PMID: 25785303

32. Gilbert C, Schack S, Pace JK 2nd, Brindley PJ, Feschotte C. A role for host-parasite interactions in the horizontal transfer of transposons across phyla. Nature. 2010 Apr 29;464(7293):1347–50. doi: 10.1038/nature08939 PMID: 20428170

33. Zhang HH, Feschotte C, Han MJ, Zhang Z. Recurrent horizontal transfers of Chaopea transposons in diverse invertebrate and vertebrate animals. Genome Biol Evol. 2014 May 27;6(6):1375–86. doi: 10.1093/gbe/evu122 PMID: 24868016

34. Tang Z, Zhang HH, Huang K, Zhang XG, Han MJ, Zhang Z. Repeat horizontal transfers of four DNA transposons in invertebrates and bats. Mol DNA. 2015 Jan 17;6(1):3. doi: 10.1016/j.moldna.2015.03.030 PMID: 27071531

35. Meany-Delman D, Rasmussen SA, Staples JE, Oduyebo T, Elibol SN, Petersen EE, et al. Zika virus and pregnancy: what obstetric health care providers need to know. Obstet Gynecol. 2016 Apr;127(4):642–8. doi: 10.1097/AOG.0000000000001378 PMID: 26889662

36. Schulter-Facchin L, Ribeiro EM, Faitoso IM, Horovitz DO, Cavalcanti DP, Pessoa A, et al. Brazilian Medical Genetics Society–Zika Embryopathy Task Force. Possible association between Zika virus infection and microcephaly - Brazil, 2015. MMWR Mortal Wkly Rep. 2016 Feb 19;65(6):159–60. doi: 10.15585/mmwr.mm6506e1 PMID: 26890059

37. Martines RB, Bhatnagar J, Keating MK, Silva-Flannery L, Muehlenbachs A, Gary J, et al. Notes from the field: evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses – Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016 Feb 19;65(6):159–60. doi: 10.15585/mmwr.mm6506e1 PMID: 26890059

38. Cugola FR, Fernandes IR, Russo FB, Freitas BC, Dias JLM, Guimarães KP, et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature. 2016 May 11;534(7606):267–71. PMID: 27279226

39. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. Geneva: World Health Organization; 2016. Available from: http://www.who.int/mediacentre/news/statements/2016/1st-emergency-committee-zika/en/ [cited 2016 Feb 19].

40. premamatory finding of no significant impact (FONSI) in support of an investigational field trial of OX513A Aedes aegypti mosquitoes. Maryland: United States Food and Drug Administration; 2016. Available from: http://www.fda.gov/downloads/AnimalVeterinary/DevelopmentApprovalProcess/GeneticEngineering/GeneticallyEngineeredAnimals/UCM487379.pdf [cited 2016 Jul 18].

41. The Guidance Framework for testing genetically modified mosquitoes. Geneva: World Health Organization; 2014. Available from: http://www.who.int/tdr/publications/year/2014/who-2014-guideline-fm-gm-mosquito/en/ [cited 2016 Jul 18].

42. Campbell H, Fitzgerald R. Follow the fear: a multi-sited approach to assessing public perceptions and attitudes towards genetically modified (GM) food. J Socio-Economics. 2008 Apr;37(2):205–16. doi: 10.1016/j. socec.2008.04.006

43. Goyal P, Gurtoo S. Factors influencing public perception: genetically modified organisms. GMO BioSci Res. 2011 Nov;2(1). doi: http://dx.doi.org/10.5376/gmo.2011.02.0001

Bull World Health Organ 2016;94:766–771 doi: http://dx.doi.org/10.2471/BLT.16.173377